Categories
Archives
- 2026
- 2025
- 2024
- 2023
Feb
03
Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented
Nov
20
Closing gaps in HS care through community engagement and scientific innovation
Nov
14
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
Oct
15
Powering the dreams of people impacted by myasthenia gravis (MG)
Oct
14
UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)
Oct
11
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
Aug
16
UCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper")
Jun
12
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
Apr
12
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
